Dapa-Active LNNCT07323524
Dapagliflozin in Active Lupus Nephritis
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 5 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Primary completion moved earlier from Jul 2029 to Jul 1, 2028 Show 5 more changesShow less
- Eligibility criteria expanded, about 5 words
- Study completion moved earlier from Jan 2030 to Sep 1, 2028
- Start date: May 19, 2026 to May 22, 2026
- Site details revised at 1 of 2 sites
- Study description expanded, about 4 words
- Notable Recruitment opened
- Start date changed from estimate of Jun 1, 2026 to May 19, 2026
- Site details revised at 2 of 2 sites
- Notable Start date: Feb 1, 2026 to Jun 1, 2026v4
- Minor Study sites: 0 to 2v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Proportion of eligible enrolled
Timeframe: 3 years
Secondary (1)
Feasibility of data collection
Arms and interventions
Dapagliflozin 10 mg dailyActive comparator
Subjects will receive masked dapagliflozin 10 mg daily for 12 weeks
Matching placebo pill dailyPlacebo comparator
Subjects will receive a matching placebo pill to take daily for 12 weeks
Drugs: Dapagliflozin (10Mg Tab) along with standard medical therapy, Placebo
Sites
2 sites in 1 country